| 摘要 |
FIELD: medicine, gastroenterology, peptides. SUBSTANCE: invention relates to variant of aprotinin with general charge from +3 to -3 at pH 7 and with amino acid Arg15 or dipeptide Arg15-Ala17 in binding site. Aprotinin variant exhibits the changed N-terminal sequence and elongation or truncation by N-end or deletion of amino acid by N-end. Aprotinin variant is taken among the following group: des-Pro2-Ser-10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, des-Pro2-Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, des-Pro2-Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, des-pro2-Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin, des-Pro2-Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin, Ser10-Arg15-Ala17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Ser17-Asp24-Thr26-Glu31-Asn41-Glu53-aprotinin, Ser10-Arg15-Ala17-Thr26-Glu31-Asn41-Glu53-aprotinin and Ser10-Arg15-Ala17-Asp24-Thr26-Asn41-Glu53-aprotinin. Invention is used for correction of state of gastroenteric tract. EFFECT: expanded assortment of serine proteases, valuable medicinal properties of aprotinin variant. 5 cl, 2 tbl, 1 dwg |
